2022
Commentary on CDC data showing an increased risk for pediatric diabetes with COVID‐19 infection
Gujral J, Tamborlane W, Nally L. Commentary on CDC data showing an increased risk for pediatric diabetes with COVID‐19 infection. Journal Of Diabetes 2022, 14: 630-632. PMID: 36073304, PMCID: PMC9512767, DOI: 10.1111/1753-0407.13311.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionIncidence of diabetesBody mass indexType of diabetesMortality Weekly ReportCommercial health insurancePrevention's MorbidityMass indexPediatric diabetesViral variantsSocial determinantsDisease controlDiabetesRecent CentersHealth insuranceCDC dataSignificant increaseInfectionWeekly reportsMorbidityIncidenceOnce-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjöström CD. Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care 2022, 45: 1833-1840. PMID: 35679098, PMCID: PMC9346995, DOI: 10.2337/dc21-2275.Peer-Reviewed Original ResearchConceptsType 2 diabetesEfficacy end pointWeekly exenatideAdverse eventsPlacebo groupPrimary efficacy end pointSecondary efficacy end pointsEnd pointMetformin monotherapyTreatment of youthInsulin therapyWeek 24Pediatric patientsWeekly injectionsDaily injectionsGlycated hemoglobinCurrent treatmentExenatideBody weightDiabetesLiraglutideWeeksHemoglobinTreatmentBaselineYouth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetes
2021
Racial and Ethnic Disparities in Comorbidities in Youth With Type 2 Diabetes in the Pediatric Diabetes Consortium (PDC).
Bacha F, Cheng P, Gal RL, Beaulieu LC, Kollman C, Adolph A, Shoemaker AH, Wolf R, Klingensmith GJ, Tamborlane WV. Racial and Ethnic Disparities in Comorbidities in Youth With Type 2 Diabetes in the Pediatric Diabetes Consortium (PDC). Diabetes Care 2021, 44: 2245-2251. PMID: 34475033, DOI: 10.2337/dc21-0143.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseType 2 diabetesNon-Hispanic blacksPediatric Diabetes ConsortiumFatty liver diseaseWorse metabolic controlRacial-ethnic disparitiesNon-Hispanic white youthManagement of youthSubsequent comorbiditiesDiabetic ketoacidosisInitial presentationLiver diseaseMean ageRegistry participantsMedical recordsC-peptideClinical dataDiabetesMetabolic controlHealth outcomesRacial-ethnic differencesEthnic disparitiesComorbiditiesRacial-ethnic groupsImpact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study.
Mauras N, Buckingham B, White NH, Tsalikian E, Weinzimer SA, Jo B, Cato A, Fox LA, Aye T, Arbelaez AM, Hershey T, Tansey M, Tamborlane W, Foland-Ross LC, Shen H, Englert K, Mazaika P, Marzelli M, Reiss AL. Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study. Diabetes Care 2021, 44: 983-992. PMID: 33568403, PMCID: PMC7985430, DOI: 10.2337/dc20-2125.Peer-Reviewed Original ResearchConceptsType 1 diabetesBrain volumeControl subjectsTotal brain volume differencesEarly-onset type 1 diabetesAge-matched control subjectsIntelligence quotientCognitive scoresWhite matter volumeBrain volume differencesContinuous glucose monitoringDiabetes groupFull-scale intelligence quotientDiabetes complicationsDiabetes controlTotal brainVerbal intelligence quotientDiabetesMatter volumeSensor glucoseCognitive testingGlucose monitoringMixed-effects modelsBrainGroup differences
2020
Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes
DuBose SN, Li Z, Sherr JL, Beck RW, Tamborlane WV, Shah VN. Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes. Journal Of Diabetes Science And Technology 2020, 15: 593-599. PMID: 32064911, PMCID: PMC8120054, DOI: 10.1177/1932296820905904.Peer-Reviewed Original ResearchConceptsEffects of exerciseSensor glucose levelsHealthy individualsResistance exerciseNadir glucoseGlucose levelsNonobese body mass indexT1D Exchange Clinic NetworkPeak postprandial glucoseBody mass indexGlucose concentrationTime of mealsNadir glucose concentrationsConsumption of alcoholMass indexPostprandial glucoseNonexercise dayAerobic exerciseExercise dayClinic networkMean changeFuture therapiesDiabetesDexcom G6Glucose monitor data
2019
“I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes
Commissariat PV, Harrington KR, Whitehouse AL, Miller KM, Hilliard ME, Van Name M, DeSalvo DJ, Tamborlane WV, Anderson BJ, DiMeglio LA, Laffel LM. “I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes. Pediatric Diabetes 2019, 21: 377-383. PMID: 31808586, PMCID: PMC7830825, DOI: 10.1111/pedi.12956.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlycemic controlDiabetes burdenSecondary caregiversEmotional burdenChildren's glycemic controlYoung childrenCare of childrenAge 5.2Parents' perceptionsCaregivers' knowledgeClinical centersSemi-structured qualitative interviewsDiabetesDiabetes educationParental burdenHealthcare providersAge groupsInsulin pumpParents' burdenT1DChildren's qualityChild's diabetesParents' knowledgeParents' confidenceGlucose management for rewards: A randomized trial to improve glucose monitoring and associated self‐management behaviors in adolescents with type 1 diabetes
Wagner JA, Petry NM, Weyman K, Tichy E, Cengiz E, Zajac K, Tamborlane WV. Glucose management for rewards: A randomized trial to improve glucose monitoring and associated self‐management behaviors in adolescents with type 1 diabetes. Pediatric Diabetes 2019, 20: 997-1006. PMID: 31271239, PMCID: PMC6786915, DOI: 10.1111/pedi.12889.Peer-Reviewed Original ResearchConceptsType 1 diabetesWithdrawal of reinforcementImproved metabolic controlProportion of daysGroup differencesSelf-management behaviorsEffect sizeEUC participantsMean A1CUsual careWeek 24Week 12Blood glucoseGlucose managementWeek 6Metabolic controlAge groupsDiabetesGlucose monitoringBaselineSMBGDurable increaseWeeksA1CWithdrawalPharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugsImpact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2DegludecInternational Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care 2019, 42: 1147-1154. PMID: 30728224, PMCID: PMC6973545, DOI: 10.2337/dc18-2316.Peer-Reviewed Original ResearchConceptsType 1 diabetesSodium-glucose cotransporter inhibitorsDiabetic ketoacidosisCotransporter inhibitorsSGLT inhibitorsNear-normal blood glucose levelsOral antidiabetes medicationsBlood glucose levelsAntidiabetes medicationsInhibitor useBlood pressureAbsolute riskMild hyperglycemiaDKA riskGlycemic variabilityConsensus reportGlucose levelsBody weightDrug AdministrationDiabetesType 1U.S. FoodMedical communityKetoacidosisInternational consensusReversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology & Therapeutics 2019, 21: 101-104. PMID: 30688521, PMCID: PMC6434586, DOI: 10.1089/dia.2018.0356.Peer-Reviewed Original ResearchConceptsType 1 diabetesFree fatty acidsSGLT2i useAspart insulinSGLT2 inhibitor therapyPlasma glucose levelsSodium-glucose cotransporterCanagliflozin treatmentEuglycemic DKARescue therapyBasal insulinInhibitor therapyRate of ketogenesisRescue treatmentBlunted increaseSubcutaneous injectionGlucose levelsTreatment studiesNormal increaseInsulinDiabetesTherapyKetogenesisFatty acidsTreatment
2018
Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry
Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW, Consortium F. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2018, 19: 1379-1384. PMID: 30175440, DOI: 10.1111/pedi.12763.Peer-Reviewed Original ResearchConceptsType 2 diabetesT2D durationT2D patientsClinical trialsEligibility criteriaPlacebo-assigned subjectsPercentage of patientsCurrent clinical trialsRestrictive eligibility criteriaBaseline HbA1cHbA1c levelsClinical characteristicsClinic registryRegistry enrollmentInvestigational treatmentPatientsCurrent trialTrialsNew drugsMonthsHbA1cRatio of femaleDiabetesRegistryEnrollmentSubstance Use in Adults With Type 1 Diabetes in the T1D Exchange
Petry NM, Foster NC, Cengiz E, Tamborlane WV, Wagner J, Polsky S. Substance Use in Adults With Type 1 Diabetes in the T1D Exchange. The Science Of Diabetes Self-Management And Care 2018, 44: 510-518. PMID: 30203721, DOI: 10.1177/0145721718799088.Peer-Reviewed Original ResearchConceptsType 1 diabetesGeneral populationSubstance usePast-year alcohol usePast-year usePsychoactive substancesDaily usePsychoactive substance usePast-month useClinical outcomesT1D ExchangeProblem useBinge drinkersT1D managementNonprescription useRegistry CenterAlcohol useStandardized instrumentsProblem drinkersAdult participantsDiabetesAdultsFrequency of useDrinkersProblematic useThe present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent useAcute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes
Bjornstad P, Laffel L, Tamborlane WV, Simons G, Hantel S, von Eynatten M, George J, Marquard J, Cherney DZI. Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes. Diabetes Care 2018, 41: dc180394. PMID: 29941496, PMCID: PMC6054503, DOI: 10.2337/dc18-0394.Peer-Reviewed Original ResearchBig Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology
Riddle MC, Bakris G, Boulton AJM, Blonde L, D’Alessio D, Greene EL, de Groot M, Hood K, Hu FB, Kahn SE, Kaul S, LeRoith D, Moses RG, Rich SS, Rosenstock J, Tamborlane WV, Wylie-Rosett J, Reynolds L. Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology. Diabetes Care 2018, 41: 1327-1329. PMID: 29934474, DOI: 10.2337/dci18-0035.Peer-Reviewed Original ResearchPersistence of abnormalities in white matter in children with type 1 diabetes
Fox LA, Hershey T, Mauras N, Arbeláez AM, Tamborlane WV, Buckingham B, Tsalikian E, Englert K, Raman M, Jo B, Shen H, Reiss A, Mazaika P, for the Diabetes Research in Children Network (DirecNet). Persistence of abnormalities in white matter in children with type 1 diabetes. Diabetologia 2018, 61: 1538-1547. PMID: 29654376, PMCID: PMC5991628, DOI: 10.1007/s00125-018-4610-6.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkersBlood GlucoseCase-Control StudiesChildChild DevelopmentChild, PreschoolCognitive DysfunctionDiabetes Mellitus, Type 1Diffusion Tensor ImagingFemaleGlycated HemoglobinHumansLeukoencephalopathiesLongitudinal StudiesMagnetic Resonance ImagingMalePrognosisRisk FactorsTime FactorsUnited StatesConceptsType 1 diabetesNon-diabetic childrenWhite matter microstructureWhite matterAltered white matter developmentContinuous glucose monitoring (CGM) profilesFractional anisotropyConclusions/interpretationThese resultsPersistence of abnormalitiesLongitudinal observational studyWhite matter growthYoung childrenWhite matter developmentMild cognitive deficitsHigher fractional anisotropyDiabetes groupClinical centersMethodsOne hundredObservational studyDiabetesInterpretationThese resultsCognitive deficitsHyperglycaemiaDiabetes researchAdverse effects
2017
Predictors of Loss to Follow-Up among Children with Type 2 Diabetes
Shoemaker A, Cheng P, Gal RL, Kollman C, Tamborlane WV, Klingensmith GJ, Clements MA, Hannon TS, Heptulla R, Less J, Wood J. Predictors of Loss to Follow-Up among Children with Type 2 Diabetes. Hormone Research In Paediatrics 2017, 87: 377-384. PMID: 28505610, DOI: 10.1159/000475595.Peer-Reviewed Original ResearchConceptsType 2 diabetesMultivariable logistic regression modelPediatric diabetes centersPredictors of lossLogistic regression modelsRace/ethnicityClinical factorsDiabetes CenterPoor complianceOdds ratioMedical careEnrollment variablesSignificant predictorsSocioeconomic factorsOlder adolescentsT2DDiabetesPatientsClinicCareRegression modelsParent educationPredictorsYearsFinal modelUnderstanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin
Tamborlane WV, Pfeiffer KM, Brod M, Nikolajsen A, Sandberg A, Peters AL, Van Name M. Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin. Current Medical Research And Opinion 2017, 33: 639-645. PMID: 28008782, DOI: 10.1080/03007995.2016.1275937.Peer-Reviewed Original ResearchConceptsBolus insulinDose timingBolus insulin therapyPrevious weekType 2 diabetesExperiences of peopleInsulin therapyTreatment optionsDiabetes educationWeb-based surveyType 1DiabetesMajority of respondentsInsulinSelf-report surveyGeneralizability of findingsT2DT1DMealWeeksHypoglycemiaRespondentsTherapyBolusPotential bias